Mirum Pharmaceuticals, Inc. Income Statement
MIRM / Health Care|8 years of annual SEC 10-K data (FY2018-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 8 fiscal years. All figures from audited SEC 10-K filings.
Mirum Pharmaceuticals, Inc. reported $521M in revenue and $23M in net loss for FY2025. Revenue has grown at a 128.5% compound annual rate over the past 4 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.41 (distress zone, below 1.8 threshold)
- Negative profit margin: -26.1%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $521.3M | $336.9M | $186.4M | $77.1M | $19.1M | $0 | - | - |
| SG&A Expense | $257.0M | $202.2M | $145.9M | $89.1M | $59.2M | $22.7M | $11.8M | $585.0K |
| R&D Expense | $186.2M | $140.6M | $102.6M | $106.8M | $131.4M | $81.6M | $43.0M | $2.3M |
| Operating Income | -$22.1M | -$87.6M | -$109.2M | -$131.2M | -$173.4M | -$104.3M | -$54.7M | -$17.4M |
| Income Tax | $1.9M | $1.0M | $991.0K | -$6.4M | $37.0K | $6.0K | $21.0K | $0 |
| Net Income | -$23.4M | -$87.9M | -$163.4M | -$135.7M | -$84.0M | -$103.3M | -$52.6M | -$17.3M |
| EPS (Basic) | -$0.47 | -$1.85 | -$4.00 | -$4.01 | -$2.77 | - | - | - |
| EPS (Diluted) | -$0.47 | -$1.85 | -$4.00 | -$4.02 | -$2.77 | - | - | - |
| Shares Outstanding | 51.9M | 48.3M | 46.7M | 37.0M | 30.6M | 25.3M | 11.5M | 899.3K |
| Operating Margin | -4.3% | -26.0% | -58.6% | -170.3% | -906.1% | - | - | - |
| Profit Margin | -4.5% | -26.1% | -87.7% | -176.0% | -438.8% | - | - | - |